On June 26, 2024, EyePoint Pharmaceuticals, Inc. hosted its R&D Day in New York City, where it presented the 2024 R&D Day Presentation, including estimated cash and investments as of June 30, 2024, and corporate updates. The company also announced clinical and regulatory developments for its lead pipeline program, DURAVYU™ (vorolanib intravitreal insert), based on its Durasert E™ sustained drug delivery technology. The Presentation and a press release were filed with the SEC and included in Exhibits 99.1 and 99.2, respectively. The data presented were preliminary and subject to change pending the completion of the company's quarterly report. EyePoint Pharmaceuticals highlighted the potential of DURAVYU™ as a treatment for serious eye diseases, including wet age-related macular degeneration (AMD), and provided updates on its Phase 2 clinical trial results, which met all primary and secondary endpoints. The company outlined plans for Phase 3 pivotal trials, aiming for FDA approval. The R&D Day also covered the company's early-stage programs and featured discussions with key opinion leaders in ophthalmology.

On June 26, 2024, EyePoint Pharmaceuticals, Inc. hosted its R&D Day in New York City, where it presented the 2024 R&D Day Presentation, including estimated cash and investments as of June 30, 2024, and corporate updates. The company also announced clinical and regulatory developments for its lead pipeline program, DURAVYU™ (vorolanib intravitreal insert), based on its Durasert E™ sustained drug delivery technology. The Presentation and a press release were filed with the SEC and included in Exhibits 99.1 and 99.2, respectively. The data presented were preliminary and subject to change pending the completion of the company's quarterly report. EyePoint Pharmaceuticals highlighted the potential of DURAVYU™ as a treatment for serious eye diseases, including wet age-related macular degeneration (AMD), and provided updates on its Phase 2 clinical trial results, which met all primary and secondary endpoints. The company outlined plans for Phase 3 pivotal trials, aiming for FDA approval. The R&D Day also covered the company's early-stage programs and featured discussions with key opinion leaders in ophthalmology.